ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RLAY Relay Therapeutics Inc

6.40
0.50 (8.47%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,706,010
Bid Price 6.30
Ask Price 6.35
News -
Day High 6.43

Low
5.70

52 Week Range

High
13.32

Day Low 5.70
Company Name Stock Ticker Symbol Market Type
Relay Therapeutics Inc RLAY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.50 8.47% 6.40 19:58:46
Open Price Low Price High Price Close Price Prev Close
5.87 5.70 6.43 6.35 5.90
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14,052 1,706,010 $ 6.10 $ 10,410,970 - 5.70 - 13.32
Last Trade Time Type Quantity Stock Price Currency
19:58:46 45 $ 6.40 USD

Relay Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
832.99M 131.18M - 31.97M -341.97M -2.61 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Relay Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RLAY Message Board. Create One! See More Posts on RLAY Message Board See More Message Board Posts

Historical RLAY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.686.775.706.051,806,754-0.28-4.19%
1 Month7.708.435.706.781,232,525-1.30-16.88%
3 Months9.5111.165.708.381,222,944-3.11-32.70%
6 Months6.4812.145.708.721,147,982-0.08-1.23%
1 Year12.8213.325.709.691,154,382-6.42-50.08%
3 Years33.8938.6055.7017.871,019,672-27.49-81.12%
5 Years33.9864.375.7020.66915,246-27.58-81.17%

Relay Therapeutics Description

Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020.

Your Recent History

Delayed Upgrade Clock